Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro

Ningke Hou(Westlake University), Qi Hu(Westlake University), Haishan Gao(Westlake University), Xijun He(Chinese Academy of Agricultural Sciences), Shuofeng Yuan(University of Hong Kong - Shenzhen Hospital), Hongtao Yu(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital), Zuyuan Shen(Hebei Medical University), Lei Shuai(Chinese Academy of Agricultural Sciences), Wenji Su(WuXi AppTec (China)), Kaiming Tang(University of Hong Kong), Qiaozhu Tan(Westlake University), Zhiyuan Wen(Guangxi Medical University), Hong Huo(Chinese Academy of Agricultural Sciences), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Vineet D. Menachery(Emory University), Jing Huang(Westlake University), Zhigao Bu(Harbin Veterinary Research Institute), You Xu(Karolinska Institutet), Craig Schindewolf(The University of Texas Medical Branch at Galveston), Gongxun Zhong(Chinese Academy of Agricultural Sciences), Jing Xue(Westlake University), Chong Wang(Chinese Academy of Agricultural Sciences), Wenyi Zhang(Institute of Microbiology), Rong Zhang(Huazhong Agricultural University), Lijing Zhang(Kunming University of Science and Technology), Chen Peng(Westlake University), Jing Zou(The University of Texas Medical Branch at Galveston), Youlang Yuan(WuXi AppTec (China)), Yu Yin(Shanghai Medical College of Fudan University), Yunkai Zhu(Army Medical University), Xuping Xie(The University of Texas Medical Branch at Galveston)
ACS Central Science
January 25, 2023
Cited by 104


Related Papers